Premium
Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial
Author(s) -
Benatar Michael,
Sanders Donald B.,
Wolfe Gil I.,
McDermott Michael P.,
Tawil Rabi
Publication year - 2012
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06780.x
Subject(s) - medicine , prednisone , epitome , ocular myasthenia , randomized controlled trial , placebo , tolerability , myasthenia gravis , surgery , anesthesia , adverse effect , alternative medicine , art , literature , pathology
Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo‐controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.